Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colestilan (MCI-196) in dialysis patients with hyperphosphatemia and dyslipidemia
NCT00542386Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Dec 2007
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in hyperphosphatemia and dyslipidemia comparing Colestilan with Placebo (2 arms). Primary endpoints: Change in Serum Phosphorus at 12 weeks and Change in LDL-Cholesterol at 12 weeks. Started Dec 2007; status: completed.
02
Drugs
colestilan
03
Conditions
hyperphosphatemiadyslipidemia
Beyond the preview
Go deeper on NCT00542386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542386.